Color Diagnostics, LLC DBA Color Health, Color
General information
Color Diagnostics, LLC DBA Color Health, Color
863 Mitten Rd.
Burlingame
California
United States - 94010
https://www.color.com/
Organization ID: 505849
863 Mitten Rd.
Burlingame
California
United States - 94010
https://www.color.com/
Organization ID: 505849
Personnel
- Robert O'Connor, Contact
Phone: (844) 352-6567
Email: bob@color.com - Jeroen Van Den Akker, Informatics staff
Phone: (844) 352-6567
Email: jeroen@color.com
Assertion criteria
Level: Assertion criteria provided
Summary of submissions to ClinVar
Total submissions: 71717
Gene
| Gene | Submissions | Last Updated |
|---|---|---|
| ACTA2 | 194 | Jan 30, 2026 |
| ACTA2-AS1 | 84 | Jan 30, 2026 |
| ACTC1 | 178 | Jan 30, 2026 |
| ALG11 | 1 | Jan 30, 2026 |
| APC | 3675 | Jan 30, 2026 |
| APOB | 92 | Jan 30, 2026 |
| APOB3'MAR | 12 | Jan 10, 2022 |
| ATM | 4468 | Jan 30, 2026 |
| ATP7B | 841 | Jan 30, 2026 |
| BAP1 | 999 | Jan 30, 2026 |
| BARD1 | 1221 | Jan 30, 2026 |
| BMPR1A | 655 | Jan 30, 2026 |
| BRCA1 | 3227 | Jan 30, 2026 |
| BRCA2 | 5397 | Jan 30, 2026 |
| BRIP1 | 1498 | Jan 30, 2026 |
| C11orf65 | 1623 | Jan 30, 2026 |
| CACNA1S | 1029 | Jan 30, 2026 |
| CDH1 | 1225 | Jan 30, 2026 |
| CDK4 | 1 | Jan 10, 2022 |
| CDKN2A | 353 | Jan 30, 2026 |
| CDKN2A-AS1 | 1 | Jan 10, 2022 |
| CHEK2 | 939 | Jan 30, 2026 |
| COL3A1 | 1135 | Jan 30, 2026 |
| DCTN5 | 1 | Jan 30, 2026 |
| DNAAF3 | 4 | Nov 6, 2018 |
| DSC2 | 799 | Jan 30, 2026 |
| DSCAS | 35 | Jan 30, 2026 |
| DSG2 | 905 | Jan 30, 2026 |
| DSG2-AS1 | 339 | Jan 30, 2026 |
| DSP | 2246 | Jan 30, 2026 |
| DSP-AS1 | 77 | Jan 30, 2026 |
| FBN1 | 1975 | Jan 30, 2026 |
| FBXO11 | 2 | Oct 26, 2017 |
| GJD2-DT | 178 | Jan 30, 2026 |
| GLA | 180 | Jan 30, 2026 |
| HNRNPH2 | 1 | Jan 30, 2026 |
| KCNH2 | 931 | Jan 30, 2026 |
| KCNK12 | 9 | May 19, 2020 |
| KCNQ1 | 626 | Jan 30, 2026 |
| KCNQ1-AS1 | 92 | Jan 30, 2026 |
| KCNQ1OT1 | 54 | Jan 30, 2026 |
| LDLR | 1087 | Jan 30, 2026 |
| LDLR-AS1 | 88 | Jan 30, 2026 |
| LMNA | 518 | Jan 30, 2026 |
| LOC101929305 | 48 | Jan 30, 2026 |
| LOC106560211 | 23 | Jan 10, 2022 |
| LOC106721785 | 4 | Apr 29, 2025 |
| LOC106736614 | 7 | Jan 30, 2026 |
| LOC107303340 | 57 | Jan 30, 2026 |
| LOC107982234 | 5 | Apr 29, 2025 |
| LOC110121269 | 191 | Jan 30, 2026 |
| LOC111589215 | 2 | Apr 29, 2025 |
| LOC113939944 | 32 | Jan 30, 2026 |
| LOC114827850 | 41 | Jan 30, 2026 |
| LOC126805877 | 33 | Jan 30, 2026 |
| LOC126806067 | 109 | Jan 30, 2026 |
| LOC126806068 | 168 | Jan 30, 2026 |
| LOC126806446 | 25 | Jan 30, 2026 |
| LOC126860438 | 30 | Jan 10, 2022 |
| LOC126861339 | 11 | Jan 30, 2026 |
| LOC126861897 | 203 | Jan 30, 2026 |
| LOC126861898 | 103 | Jan 30, 2026 |
| LOC126862124 | 31 | Jan 30, 2026 |
| LOC126862571 | 427 | Jan 30, 2026 |
| LOC126862902 | 60 | Jan 30, 2026 |
| LOC129390903 | 45 | Jan 30, 2026 |
| LOC129391106 | 21 | Jan 30, 2026 |
| LOC129929542 | 5 | Jan 30, 2026 |
| LOC129931597 | 19 | Jan 30, 2026 |
| LOC129933707 | 35 | Jan 30, 2026 |
| LOC129994371 | 7 | Jan 30, 2026 |
| LOC129999660 | 20 | Apr 29, 2025 |
| LOC130001603 | 27 | Jan 30, 2026 |
| LOC130009838 | 7 | Jan 30, 2026 |
| LOC130057019 | 16 | Jan 30, 2026 |
| LOC130057222 | 2 | Nov 6, 2018 |
| LOC130057352 | 18 | Jan 30, 2026 |
| LOC130058210 | 1 | Jan 30, 2026 |
| LOC130059290 | 4 | May 19, 2020 |
| LOC130061310 | 12 | Apr 29, 2025 |
| LOC130062340 | 30 | Jan 30, 2026 |
| LOC130062899 | 78 | Jan 30, 2026 |
| LRRFIP2 | 1 | Jan 30, 2026 |
| MEN1 | 215 | Jan 30, 2026 |
| MHRT | 296 | Jan 30, 2026 |
| MIR3606 | 2 | Jan 30, 2026 |
| MIR6886 | 19 | Jan 30, 2026 |
| MITF | 1 | Jan 30, 2026 |
| MLH1 | 1351 | Jan 30, 2026 |
| MSH2 | 1897 | Jan 30, 2026 |
| MSH6 | 2808 | Jan 30, 2026 |
| MUTYH | 1009 | Jan 30, 2026 |
| MYBPC3 | 1483 | Jan 30, 2026 |
| MYH11 | 1822 | Jan 30, 2026 |
| MYH7 | 1660 | Jan 30, 2026 |
| MYL2 | 197 | Jan 30, 2026 |
| MYL3 | 170 | Jan 30, 2026 |
| NBN | 30 | Jan 10, 2022 |
| NDE1 | 764 | Jan 30, 2026 |
| NF2 | 199 | Jan 30, 2026 |
| OTC | 96 | Jan 30, 2026 |
| PALB2 | 1738 | Jan 30, 2026 |
| PCSK9 | 835 | Jan 30, 2026 |
| PHF7 | 1 | May 19, 2020 |
| PKD1 | 16 | Jan 30, 2026 |
| PKP2 | 884 | Jan 30, 2026 |
| PMS2 | 1571 | Jan 30, 2026 |
| POLE | 1 | Apr 29, 2025 |
| PRKAG2 | 472 | Jan 30, 2026 |
| PTEN | 426 | Jan 30, 2026 |
| RAD51C | 615 | Jan 30, 2026 |
| RAD51D | 568 | Jan 30, 2026 |
| RAD51L3-RFFL | 568 | Jan 30, 2026 |
| RB1 | 315 | Jan 30, 2026 |
| RB1-DT | 1 | Jan 30, 2026 |
| RET | 581 | Jan 30, 2026 |
| RPL36A-HNRNPH2 | 180 | Jan 30, 2026 |
| RYR1 | 2656 | Jan 30, 2026 |
| RYR2 | 3418 | Jan 30, 2026 |
| SCN5A | 1669 | Jan 30, 2026 |
| SDHAF2 | 97 | Jan 30, 2026 |
| SDHB | 142 | Jan 30, 2026 |
| SDHC | 61 | Jan 30, 2026 |
| SDHD | 73 | Jan 30, 2026 |
| SMAD3 | 301 | Jan 30, 2026 |
| SMAD4 | 493 | Jan 30, 2026 |
| STK11 | 797 | Jan 30, 2026 |
| TGFBR1 | 258 | Jan 30, 2026 |
| TGFBR2 | 400 | Jan 30, 2026 |
| TMEM43 | 485 | Jan 30, 2026 |
| TNNI3 | 251 | Jan 30, 2026 |
| TNNT2 | 297 | Jan 30, 2026 |
| TOE1 | 48 | Jan 30, 2026 |
| TP53 | 724 | Jan 30, 2026 |
| TPM1 | 248 | Jan 30, 2026 |
| TPM1-AS | 2 | Nov 6, 2018 |
| TSC1 | 491 | Jan 30, 2026 |
| TSC2 | 1258 | Jan 30, 2026 |
| VHL | 158 | Jan 30, 2026 |
| WT1 | 103 | Jan 30, 2026 |
Condition
| Name | Submissions | Last Updated |
|---|---|---|
| Cardiac arrhythmia | 3226 | Jan 30, 2026 |
| Cardiomyopathy | 14210 | Jan 30, 2026 |
| Fabry disease | 180 | Jan 30, 2026 |
| Familial hypercholesterolemia | 1927 | Jan 30, 2026 |
| Familial thoracic aortic aneurysm and aortic dissection | 6085 | Jan 30, 2026 |
| Hereditary cancer-predisposing syndrome | 37687 | Jan 30, 2026 |
| Hereditary pheochromocytoma and paraganglioma | 373 | Jan 30, 2026 |
| Hypercholesterolemia, familial, 1 | 87 | Dec 21, 2017 |
| Malignant hyperthermia, susceptibility to, 1 | 2656 | Jan 30, 2026 |
| Malignant hyperthermia, susceptibility to, 5 | 1029 | Jan 30, 2026 |
| Multiple endocrine neoplasia, type 1 | 215 | Jan 30, 2026 |
| Multiple endocrine neoplasia, type 2 | 581 | Jan 30, 2026 |
| Neurofibromatosis, type 2 | 199 | Jan 30, 2026 |
| Ornithine carbamoyltransferase deficiency | 96 | Jan 30, 2026 |
| Retinoblastoma | 315 | Jan 30, 2026 |
| Tuberous sclerosis syndrome | 1749 | Jan 30, 2026 |
| Von Hippel-Lindau syndrome | 158 | Jan 30, 2026 |
| Wilms tumor 1 | 103 | Jan 30, 2026 |
| Wilson disease | 841 | Jan 30, 2026 |
Testing in GTR
| Disease name | Number of tests |
|---|---|
| Aneurysm-osteoarthritis syndrome | 1 test |
| Aortic aneurysm, familial thoracic, SMAD3 related | 2 tests |
| Arrhythmogenic right ventricular cardiomyopathy | 2 tests |
| Ataxia-telangiectasia syndrome | 2 tests |
| Breast and colorectal cancer, susceptibility to | 3 tests |
| Breast and/or ovarian cancer | 3 tests |
| Breast cancer, early-onset | 2 tests |
| Breast cancer, familial male | 3 tests |
| Breast cancer, susceptibility to | 3 tests |
| Brugada syndrome | 2 tests |
| Catecholaminergic polymorphic ventricular tachycardia | 1 test |
| Catecholaminergic polymorphic ventricular tachycardia 1 | 1 test |
| Central core myopathy | 1 test |
| Colorectal cancer | 3 tests |
| Colorectal cancer, susceptibility to | 1 test |
| Colorectal cancer, susceptibility to, 12 | 1 test |
| Congenital long QT syndrome | 1 test |
| Drug metabolism or response | 1 test |
| Ehlers-Danlos syndrome, type 4 | 2 tests |
| Familial adenomatous polyposis 2 | 1 test |
| Familial aortopathy | 2 tests |
| Familial cancer of breast | 2 tests |
| Familial colorectal cancer | 3 tests |
| Familial hypercholesterolemia | 2 tests |
| Familial medullary thyroid carcinoma | 1 test |
| Familial prostate cancer | 1 test |
| Fanconi anemia complementation group J | 3 tests |
| Fanconi anemia complementation group N | 3 tests |
| Hereditary breast ovarian cancer syndrome | 3 tests |
| Hereditary cancer-predisposing syndrome | 2 tests |
| Hereditary diffuse gastric adenocarcinoma | 1 test |
| Hereditary nonpolyposis colon cancer | 1 test |
| Heritable Thoracic Aortic Disease | 2 tests |
| Hirschsprung disease, susceptibility to, 1 | 1 test |
| Hypercholesterolemia, familial, 1 | 1 test |
| Jervell and Lange-Nielsen syndrome 1 | 2 tests |
| Li-Fraumeni syndrome | 2 tests |
| Loeys-Dietz syndrome | 2 tests |
| Loeys-Dietz syndrome 1 | 2 tests |
| Loeys-Dietz syndrome 2 | 2 tests |
| Long QT syndrome | 2 tests |
| Long QT syndrome 1 | 1 test |
| Lynch syndrome | 1 test |
| Lynch syndrome 1 | 1 test |
| Malignant hyperthermia | 1 test |
| Malignant hyperthermia, susceptibility to | 1 test |
| Marfan Syndrome/Loeys-Dietz Syndrome/Familial Thoracic Aortic Aneurysms and Dissections | 2 tests |
| Marfan syndrome | 2 tests |
| Multiple endocrine neoplasia type 2A | 1 test |
| Multiple endocrine neoplasia type 2B | 1 test |
| Multiple endocrine neoplasia, type 1 | 1 test |
| Neurofibromatosis, type 2 | 1 test |
| Ornithine carbamoyltransferase deficiency | 1 test |
| Ovarian cancer | 2 tests |
| PTEN hamartoma tumor syndrome | 2 tests |
| Pancreatic cancer, adult | 1 test |
| Pancreatic cancer, susceptibility to, 1 | 1 test |
| Peutz-Jeghers syndrome | 2 tests |
| Pheochromocytoma | 1 test |
| Pheochromocytoma/paraganglioma syndrome 2 | 1 test |
| Primary dilated cardiomyopathy | 1 test |
| Primary familial dilated cardiomyopathy | 1 test |
| Primary familial hypertrophic cardiomyopathy | 2 tests |
| Prostate cancer, hereditary, 1 | 1 test |
| Retinoblastoma | 1 test |
| Tuberous sclerosis 1 | 1 test |
| Von Hippel-Lindau syndrome | 1 test |
| Wilms tumor 1 | 1 test |
| Wilson disease | 1 test |
